The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules.
J. S. Kauh
No relevant relationships to disclose
G. Shapiro
No relevant relationships to disclose
R. B. Cohen
Consultant or Advisory Role - Millennium
Research Funding - Millennium
J. W. Clark
No relevant relationships to disclose
R. D. Harvey
No relevant relationships to disclose
J. M. Cleary
No relevant relationships to disclose
D. Mahalingam
No relevant relationships to disclose
S. Kuan
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
A. McDonald
Employment or Leadership Position - Millennium
A. Berger
Employment or Leadership Position - Millennium
B. Dezube
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
J. Sarantopoulos
No relevant relationships to disclose